您好,欢迎您

【ESMO 2022】已出炉的这些消化肿瘤presentations值得关注!

08月17日
ESMO22
编译:肿瘤资讯
来源:肿瘤资讯

金秋时节,2022ESMO大会浪漫来袭!今年ESMO大会预计于9月9日至13日(欧洲中部夏令时间,CEST)以线上结合线下形式,在法国首都巴黎凡尔赛门展厅举办。

目前,【肿瘤资讯】从官网获得现有资讯,将已公布的消化肿瘤及NETs and endocrine tumours领域值得关注的研究题目整理如下,与君共赏!

专场:Proffered Paper session 1: GI, lower digestive

摘要号:314O

Adjuvant hyperthermic intraperitoneal chemotherapy in locally advanced colon cancer (HIPECT4): a randomized,phase 3 study. 

局部晚期结肠癌的辅助热腹腔内化疗 (HIPECT4):一项随机的 3 期研究   

第一作者:Alvaro Arjona-Sanchez (Cordoba, Spain)

专场:Proffered Paper session 2: GI, upper digestive

摘要号:1203O

FOLFOX plus nivolumab and ipilimumab versus FOLFOX induction followed by nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – results from the randomized phase 2 Moonlight trial of the AIO.

FOLFOX加纳武利尤单抗和伊匹木单抗对比 FOLFOX 诱导后加纳武利尤单抗和伊匹木单抗治疗先前未治疗的胃或胃食管交界处晚期或转移性腺癌患者 - 来自 AIO 的随机 2 期 Moonlight 试验 

第一作者:Sylvie Lorenzen (Munich, Germany)

专场:Proffered Paper session 2: GI, lower digestive

摘要号:315O

Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: safety and efficacy for phase 1b full expansion cohort 

Sotorasib 联合帕妥珠单抗治疗难治性 KRAS G12C 突变结直肠癌:1b期完全扩展队列的安全性和疗效

第一作者:Yasutoshi Kuboki (Kashiwa, Japan)

摘要号:316O

Genomic mechanisms of acquired resistance of patients (pts) with BRAF V600E-mutant (mt) metastatic colorectal cancer (mCRC) treated in the BEACON study 

BEACON 研究中BRAF V600E 突变 (mt) 转移性结直肠癌 (mCRC) 患者(pts) 发生获得性耐药的基因组机制

第一作者:Scott Kopetz (Houston, United States of America)

专场:Proffered Paper session: NETs and endocrine tumours

摘要号:887O

First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium –Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: results of the OCLURANDOM trial  

一项在不可切除的进展性神经内分泌胰腺肿瘤患者中研究肽受体放射性核疗法联合177Lutetium–Octreotate(OCLU) 的抗肿瘤疗效的首次多中心、随机、II期试验:OCLURANDOM试验结果  

第一作者:Eric Baudin (Villejuif, France)

摘要号:1644O

Donafenib in Locally Advanced/Metastatic, Radioactive Iodine-Refractory, Differentiated Thyroid Cancer: A Randomized, Double-blind, Placebo-controlled, Multi-Center Phase III Clinical Trial (DIRECTION)

多纳非尼治疗局部晚期/转移性、放射性碘难治性、分化型甲状腺癌:一项随机、双盲、安慰剂对照、多中心 III 期临床试验(DIRECTION) 

第一作者:林岩松,北京协和医院 (中国,北京)

专场:Mini Oral session: GI, upper digestive

摘要号:1296MO

PRODIGE 29-UCGI 26(NEOPAN): A Phase III randomised trial comparing chemotherapy with Folfirinox or gemcitabine in locally advanced pancreatic carcinoma (LAPC)

PRODIGE 29-UCGI 26(NEOPAN):一项对比化疗与 Folfirinox或吉西他滨治疗局部晚期胰腺癌 (LAPC) 的 III 期随机试验 

第一作者:Michel P. Ducreux (Villejuif, CEDEX, France)

摘要号:52MO

A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-naïve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)

度伐利尤单抗+tremelimumab+吉西他滨/+吉西他滨+顺铂vs.吉西他滨+顺铂在初治胆管癌和胆囊癌患者中的对比:IMMUCHEC 随机II 期试验

第一作者:Arndt Vogel (Hannover, Germany)

摘要号:53MO

Nal-IRI and 5-FU/LV Compared to 5-FU/LV in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NALIRICC – AIO-HEP-0116)  

Nal-IRI + 5-FU/LV vs. 5-FU/LV在先前接受过基于吉西他滨治疗的胆管癌和胆囊癌患者中的疗效对比 (NALIRICC – AIO-HEP-0116) 

第一作者:Arndt Vogel (Hannover, Germany)

摘要号: 54MO

Quality of Life (QoL) and Value of Health (V-He) in advanced biliary cancers (ABC) treated with second-line Active-Symptom-Control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+FOLFOX) in the randomised phase III, multi-centre, open-label ABC-06 trial

随机、III期、多中心、开放性 ABC-06 试验:接受二线对症治疗 (ASC) 单药或 ASC 联合奥沙利铂/5-FU 化疗 (ASC + FOLFOX) 的晚期胆道癌 (ABC) 患者的生活质量 (QoL) 和健康价值 (V-He)

第一作者:Angela Lamarca (Madrid, Spain)

摘要号:1204MO

PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus Durvalumab and FOLFIRI plus Durvalumab plus Tremelimumab in second-line treatment of patients with advanced gastric or gastro-oesophageal junction adenocarcinoma.

PRODIGE 59 - DURIGAST 试验——一项随机 II 期研究:评估FOLFIRI +度伐利尤单抗 vs. FOLFIRI + 度伐利尤单抗+Tremelimumab在晚期胃或胃食管结合部腺癌患者的二线治疗效果

第一作者:David Tougeron (Poitiers, CEDEX, France)

专场:Mini Oral session: GI, lower digestive

摘要号:317MO

Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: an ACCENT/IDEA pooled analysis of 12 trials

含奥沙利铂的辅助化疗在老年 III 期结肠癌患者中的疗效:12项试验的 ACCENT/IDEA 汇总分析  

第一作者:Claire Gallois (Paris, France)

摘要号:318MO

Circulating Tumour DNA (ctDNA) Dynamics, CEA and Sites of Recurrence for the Randomised DYNAMIC Study: Adjuvant Chemotherapy (ACT) Guided by ctDNA Analysis in Stage II Colon Cancer (CC) 

DYNAMIC随机研究的循环肿瘤 DNA (ctDNA) 动力学、CEA 和复发部位:II 期结肠癌 (CC) 中以 ctDNA 分析为指导的辅助化疗 (ACT) 

第一作者:Jeanne Tie (Melbourne, VIC, Australia)

摘要号:319MO

Real-world monitoring of circulating tumor DNA reliably predicts cancer recurrence in patients with resected stages I-III colorectal cancer

循环肿瘤 DNA 的真实世界监测可靠预测 I-III 期结直肠癌切除患者的癌症复发  

第一作者:Stacey A. Cohen (Seattle, United States of America)

摘要号:320MO

A phase I clinical trial of regorafenib, ipilimumab, and nivolumab (RIN) in chemotherapy resistant MSS metastatic colorectal cancer (mCRC)

瑞戈非尼、伊匹木单抗和纳武利尤单抗 (RIN) 治疗化疗耐药的MSS转移性结直肠癌 (mCRC)患者的 I 期临床试验

第一作者:Marwan G. Fakih (Duarte, CA, United States of America)

专场:Mini Oral session: NETs and endocrine tumours

摘要号:1645MO

Durvalumab (D) Plus Tremelimumab (T) for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - the DUTHY (GETNE-T1812) Trial 

度伐利尤单抗(D)+ Tremelimumab (T) 治疗进行性、难治性晚期甲状腺癌患者 - DUTHY (GETNE-T1812) 试验

第一作者:Jaume Capdevila Castillon (Barcelona, Spain)

摘要号:1646MO

Phase II ATLEP Trial: Final results for Lenvatinib/Pembrolizumab in Metastasized Anaplastic and Poorly Differentiated Thyroid Carcinoma

II 期 ATLEP 试验:仑伐替尼/帕博利珠单抗在转移性间变性和低分化甲状腺癌中的最终结果 

第一作者:Christine Dierks (Halle (Saale), Germany)

摘要号:1647MO

BRAF mutated anaplastic thyroid carcinoma: clinical characteristics and outcome under BRAF inhibitors and chemotherapy in real life practice, a multicentric retrospective study of the French ENDOCAN TUTHYREF network.

BRAF 抑制剂和化疗在BRAF突变的间变性甲状腺癌患者的真实世界临床特征和结果:法国ENDOCAN TUTHYREF 网络的多中心回顾性研究

第一作者:Christelle De la Fouchardiere (Lyon, CEDEX, France)

摘要号:889MO

Emergence of Clonal hematopoiesis after Peptide Receptor Radionuclide Therapy for Neuroendocrine tumors 

神经内分泌肿瘤经肽受体放射性核素治疗后出现克隆性造血  

第一作者:Rachel El Ferkh (Villejuif, Cedex, France)

摘要号:889MO 

Comparative Expression of Driver Transcription Factors in Extra-Pulmonary Small Cell Carcinoma 

驱动转录因子在肺外小细胞癌中的表达对比

第一作者:Stephen Liu (Washington, United States of America)

摘要号:890MO

Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients  

晚期消化道神经内分泌癌患者液体活检与固体活检的突变谱

第一作者:Halfdan Sorbye (Bergen, Norway)

摘要号:496MO

Final Overall Survival results from the NICE-NEC trial (GETNE-T1913). A phase II study of nivolumab and platinum-doublet chemotherapy (CT) in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin  NICE-NEC

GETNE-T1913 II 期试验的最终总体生存结果:纳武利尤单抗和铂类双药化疗 (CT) 在未经治疗的胃肠胰腺 (GEP) 或未知 (UK) 来源的晚期 G3 神经内分泌肿瘤 (NEN) 

第一作者:Maria Carmen Riesco Martinez (Madrid, Ontario, Spain)

摘要号:1MO

An Open-Label, Phase II Trial of Cabozantinib for Advanced Adrenocortical Carcinoma

卡博替尼治疗晚期肾上腺皮质癌的开放标签 II 期试验

第一作者:Matthew T. Campbell (Houston, United States of America)

摘要号:2MO

EO2401 (EO) therapeutic vaccine for patients (pts) with adrenocortical carcinoma (ACC) and malignant pheochromocytoma/paraganglioma (MPP): phase 1/2 SPENCER study

EO2401(EO)治疗性疫苗用于肾上腺皮质癌(ACC) 和恶性嗜铬细胞瘤/副神经节瘤 (MPP) 患者 (pts):1/2 期 SPENCER 研究

第一作者:Eric Baudin (Villejuif, France)


ESMO大会的LBA(Latest Breaking Abstract)研究更新中!

 

以上已公布的研究,你最看好哪一个?快在评论区告诉我们吧!


扫码关注专栏,获取更多ESMO大会资讯!

20220810-111021.jpg

责任编辑:肿瘤资讯-Bree
排版编辑:肿瘤资讯-Morri


所属专栏
评论
08月18日
储华健
扬州中医院 | 肿瘤内科
已出炉的这些消化肿瘤/内分泌肿瘤presentations值得关注!
08月18日
黄丽琼
泉州德诚医院 | 肿瘤科
【ESMO 2022】已出炉的这些消化肿瘤/内分泌肿瘤presentations值得关注!
08月18日
郭忠强
曲沃县人民医院 | 肿瘤科
局部晚期结肠癌的辅助热腹腔内化疗